MKI67 and non-small cell lung carcinoma: Finally, our findings suggest that monitoring the PD‐L1 and Ki67 expression in CTCs of NSCLC patients treated with pembrolizumab, might improve the selection of those patients that would potentially benefit from this therapy, reduce the medical cost, tailor patient's treatment, and improve the quality of patient's life.